Literature DB >> 3068038

Effect of infusion rate on amphotericin B-associated febrile reactions.

J D Cleary1, D Weisdorf, C V Fletcher.   

Abstract

Our objective was to prospectively study febrile and chill reactions associated with two amphotericin B (AB) infusion rates, slow (2-hour) versus rapid (45 minute). Seventeen consenting bone marrow transplant recipients in whom AB was to be initiated for documented or suspected fungal infections were recruited. After standardized premedication, patients received eight daily AB infusions (0.5 mg/kg/d, concentration 0.25 mg/ml). Rate was assigned using a randomized, crossover pair design. Axillary temperature, chills, and meperidine dose required to resolve chills were monitored for each infusion. For the first pair of infusions, fever (defined as a rise of 1 degree C) occurred frequently, in 12 of 17 (70.5 percent) and 13 of 17 patients (76.4 percent), with a mean rise of 1.7 degrees C (range 1.1-3.7) and 1.7 degrees C (1.1-3.5) degrees for the 45-minute and 2-hour infusions, respectively (p greater than 0.10). Chills were observed in 15 of 17 (88.2 percent) and 14 of 17 (82.3 percent) recipients of the 45-minute and 2-hour infusions, respectively. The time of onset (p greater than 0.10) and the duration of chills (p = 0.08) were similar for both infusion rates. Meperidine requirements for rapid and slow infusions were similar as well (p = 0.12). These data suggest that for patients free of preexisting renal and cardiac disease, rapid AB infusions are well tolerated and produce adverse reactions (fever and chills) similar in nature and severity to slower infusions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3068038     DOI: 10.1177/106002808802201005

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  8 in total

1.  Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations.

Authors:  E C Oldfield; P D Garst; C Hostettler; M White; D Samuelson
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

2.  Effect of infusion rates on toxicity of amphotericin B.

Authors:  H D Davies; A Matlow; S King; G Koren
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

3.  Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B.

Authors:  M E Ellis; A A al-Hokail; H M Clink; M A Padmos; P Ernst; D G Spence; W N Tharpe; V F Hillier
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B.

Authors:  M Simitsopoulou; E Roilides; J Dotis; M Dalakiouridou; F Dudkova; E Andreadou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia.

Authors:  M Arning; A H Heer-Sonderhoff; A Wehmeier; W Schneider
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

6.  Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells.

Authors:  J D Cleary; S W Chapman; R L Nolan
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

7.  Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis.

Authors:  R Lu; C Hollingsworth; J Qiu; A Wang; E Hughes; X Xin; K M Konrath; W Elsegeiny; Yoon-Dong Park; L Atakulu; J C Craft; E C Tramont; R Mannino; P R Williamson
Journal:  mBio       Date:  2019-05-28       Impact factor: 7.867

Review 8.  Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.

Authors:  Jill Adler-Moore; Russell E Lewis; Roger J M Brüggemann; Bart J A Rijnders; Andreas H Groll; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.